IP Verse

Polpharma patent opposition analysis

CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Latest oppositions filed by Polpharma

Explore patent oppositions filed by Polpharma against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 21, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025
EP3237004
Predicting Outcome Of Treatment With An Anti- 4 7 Integrin AntibodyMILLENNIUM PHARMACEUTICALSFeb 7, 2025
EP3529360
Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein ReductionNOVARTISJan 15, 2025
EP3474820
Glp-1 Compositions And Uses ThereofNOVO NORDISKNov 7, 2024
EP2395968
Pharmaceutical Composition Comprising Glucopyranosyl Diphenylmethane Derivatives, Pharmaceutical Dosage Form Thereof, Process For Their Preparation And Uses Thereof For Improved Glycemic Control In A PatientBOEHRINGER INGELHEIMOct 10, 2024
EP3595667
Pharmaceutical Compositions Comprising A Jak InhibitorALFASIGMASep 20, 2024
EP3999643
Methods Of Treating Or Preventing Spinal Muscular AtrophyBIOGEN MAAug 20, 2024
EP3270909
Fixed Dose Combinations Comprising Etc1002 And One Or More Statins For Treating Or Reducing Cardiovascular RiskESPERION THERAPEUTICSJul 31, 2024
EP3626270
New UseNOVARTISJul 10, 2024
EP3542790
Compositions Comprising A Delivery Agent And Preparation ThereofNOVO NORDISKJun 13, 2024

Top competitors of Polpharma

Top competitors of Polpharma based on patent oppositions.